|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
Suite 400,Boston,Massachusetts,US
|
|
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
|
Inozyme Pharma Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Inozyme Pharma email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Inozyme Pharma customer service number in your country click here to find.
Doug Treco is the CEO of Inozyme Pharma. To contact Doug Treco email at [email protected] or [email protected]. Or you may call 617-401-4062
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.